Back to catalogue
№ 124 22 filings · 2022-05-27 → 2026-05-29

CLEAN POWER HYDROGEN PLC

CPH2
Energy Share price 1.35p Market cap £9.06m Overall fit 35 /1000

Poor fit on every pillar: only a thin data-centre-backup AI angle, valuation requires multiples of revenue that don't yet exist, balance sheet is on a dilution treadmill with going-concern flags, and trading is currently suspended. The price implies the bull case must already be true.

Fair value range 5p–30p Mid case · £88m
Absolute upside +871% vs current market cap
Conviction 4/5 confidence in overvalued call
Supports the call
  • Pre-revenue (£4k H1 2025 revenue) vs £6.8bn market cap is qualitatively indefensible
  • September 2025 placing priced at 5p with director participation — recent independent price reference
  • Trading suspension 29 May 2026 indicates the price is itself under official review
Limits the call
  • Cause of 29 May 2026 suspension is undisclosed — a transformative event cannot be ruled out
  • Licensing-model upside is genuinely option-like and hard to probability-weight precisely
Methodology

Probability-weighted scenarios anchored on NAV, orderbook and licensing optionality

In one line · bull case

Genuinely differentiated membrane-free electrolyser technology with first customer validation, but at a £6.8bn market cap on near-zero revenue the price already requires the 4GW 2030 target to be substantially delivered.

In one line · biggest risk

Shares are suspended pending an announcement (29 May 2026) with the cause undisclosed; combined with a 12-month cash runway and a history of dilutive raises, the risk of severe and permanent capital loss from current levels is high.

Drivers
AI beneficiary 30 /100
Data-centre backup-power is mentioned as a target vertical but is not a current revenue source; AI-driven power demand is a thesis tailwind not a captured economic.
Operating leverage 55 /100
Licensing model is theoretically high-leverage but currently invisible — onerous contracts show first units are below breakeven; meaningful leverage only at scale not yet visible.
Earnings vs expectations 15 /100
No formal financial guidance, but operational milestones (FAT, SAT, first revenue) have consistently slipped year after year.
Growth momentum 25 /100
Revenue is effectively zero; first material revenue still pushed out to Q3 2026; momentum is on the milestone narrative, not the P&L.
Moat 35 /100
Patented membrane-free technology and six patent families provide some IP protection but the competitive position is unproven at scale.
Earnings quality 18 /100
Heavy capitalisation of development costs with subsequent £5.6m impairment in 2024, recurring onerous-contract provisions, multiple inventory write-downs.
Management quality 28 /100
Technology delivery is genuine, but repeated timeline misses and dilutive raises at falling prices (7.5p → 5p) raise capital-allocation concerns.
Cyclicality 50 /100
Demand is policy/transition-cycle driven; sensitive to hydrogen subsidy regimes and renewable curtailment economics.
Leverage 35 /100
Net cash position but burning ~£6m/year with going-concern uncertainty flagged by auditor; balance sheet fragile not from debt but from cash runway.
Value-trap signals · 7
  • Repeated dilution at falling share prices (7.5p Dec 2024 → 5p Sep 2025)
  • Auditor flagged material going concern uncertainty in 2024 annual report
  • £9.1m of impairments in FY2024 (capitalised development, inventory, PP&E)
  • Recurring onerous-contract provisions on the first commercial unit
  • Multiple guidance misses on FAT, SAT and first-revenue timing
  • CEO taking 20% salary in shares to preserve cash (July 2025)
  • Trading suspension on 29 May 2026 with undisclosed reason

Clean Power Hydrogen plc (CPH2) — Investment Research Note

Executive summary

CPH2 is a UK-based developer of patented membrane-free electrolysers (MFE) for green hydrogen and high-purity oxygen production, currently pre-revenue with its first commercial 1MW MFE220 unit expected to generate revenue only in Q3 2026 2026-03-30 trading update. The operating trajectory across the period is a decade-long R&D push that finally reached a customer Site Acceptance Test of the smaller MFE110 in May 2025 2025-09-30 interim, two emergency dilutive equity raises within nine months at 7.5p and then 5p, recurring impairments (£9.1m in FY2024) and a temporary trading suspension on 29 May 2026 2026-05-29 RNS. The single most important point for valuation today: a £6,827m market cap on a pre-revenue, repeatedly-diluted, going-concern-flagged technology company implies a valuation gap of roughly two orders of magnitude vs. defensible fundamentals — and the suspension on 29 May 2026 (without disclosed cause) heightens the risk of permanent capital loss.

Fair value estimate

Methodology: Probability-weighted scenario / option-value approach (DCF is not defensible — the company has £4k of revenue in H1 2025 and £0 in prior years). I anchor on (a) the contracted orderbook of four MFE220 units worth ~£5m of future revenue 2025-08-28 placing, (b) net assets of £8.8m at 30 June 2025 2025-09-30 interim, and (c) optionality on the licensing model (Hidrigin 2GW, Kenera 2GW exclusive Middle East, Fabrum NZ/AUS) 2025-05-01 final results.

Scenario build (per share, in pence; market cap in £m):

  • Bear (technology fails or further dilution at distressed pricing): NAV-only value of c.£10m mcap, or ~2p/share
  • Base (orderbook delivers, modest licensing royalty traction, further £15-25m dilution to fund growth): 10-15× current revenue run-rate possible by 2028, supports perhaps £50-100m mcap, or ~10-20p/share
  • Bull (full execution of 4GW target by 2030, licensing model scales): perhaps £200-400m mcap on 2027 visibility, or ~40-80p/share

Fair value range: 5p – 30p per share, implying mcap of £25m – £150m.

Vs. latest disclosed market cap of £6,827.4m: downside of c.98%. The implied price of 1360p is wholly inconsistent with anything I can defend from the filings, and is consistent with a speculative blow-off that the 29 May 2026 trading suspension may now be addressing.

Sector context

ICB classification (Energy) is correct but unhelpful — CPH2 is more accurately green-hydrogen technology / cleantech. Quality is below typical Energy peers (no production, no cashflow, repeated equity raises). Listed peers/comparables: ITM Power (ITM.L) and AFC Energy (AFC.L) are the closest UK-listed hydrogen technology comparators, both of which themselves have struggled with the gap between hydrogen narrative and revenue. Ceres Power (CWR.L) is a more mature licensing-model fuel cell peer worth referencing for the licensing economics CPH2 aspires to.

Investment thesis (at a fair price, NOT at 1360p)

  • Patented, differentiated technology with first SAT validation: The MFE110 completed Site Acceptance Test at Northern Ireland Water in May 2025 producing 99.999mol% hydrogen and 99.7wt% oxygen, the first independent third-party verification of the technology working at customer scale 2025-09-30 interim. Membrane-free design avoids platinum/iridium/PFA, theoretically lower LCOH at variable wind/solar load.
  • Capital-light licensing optionality: Activated licence agreements with Kenera (H&P subsidiary, 2GW Middle East exclusive), Hidrigin (2GW Ireland), and Fabrum (NZ/AUS), targeting 3GW of the 4GW 2030 production target via licensees 2025-08-28 placing memorandum. If even a fraction monetises, royalty economics on a £6.8m FY2024 administrative cost base would be highly accretive.
  • Decentralised "mission-critical" market positioning: Six target verticals — wastewater (NIW reported 13% energy reduction from MFE-produced oxygen), data-centre backup, biomass, grid support, life sciences, return-to-base mobility 2025-08-28 placing. Data-centre angle is the one (thin) AI link.

Key risks

  • Going concern / dilution treadmill: H1 2025 cash £1.8m, £7.4m raised in September 2025 at 5p (a 33% discount to the January 2025 raise at 7.5p) and the auditor's 2024 report flagged material uncertainty re going concern 2025-05-01 final results, 2025-09-30 interim. The forecast only funds to SAT of the first MFE220 (Q3 2026) — another raise is essentially certain, on dilutive terms if the share price is rational.
  • Trading suspension 29 May 2026: The shares were suspended at the company's request "pending an announcement" 2026-05-29 RNS. The market cap of £6.8bn was computed on the last traded price; a resumption announcement (capital raise, M&A, profit warning, accounting issue, share-consolidation/clarification) is the dominant near-term catalyst and the cause is not disclosed.
  • Repeated execution slippage: FAT originally guided for Q2 2024 was completed in September 2024; first commercial MFE220 revenue was guided multiple times (initially 2024, then 2025, then H1 2026, now Q3 2026) 2024-04-19 FY23 results, 2024-09-27 H1 2024 results, 2026-03-30 update. Onerous-contract losses of £655k in H1 2025 and £538k in 2024 indicate margin reality is below initial pricing 2025-09-30 interim.

Operating leverage

The licensing-led model is, in theory, high-operating-leverage: a fixed £5-6m/year administrative cost base 2025-05-01 final results generates incremental royalty income at near-100% gross margin once licensees ramp. In practice this is invisible in the financials — gross profit is essentially zero (H1 2025 revenue £4k, COGS £4k), so any commentary on incremental contribution margin is speculative. The H1 2025 onerous contract loss of £655k suggests the MFE220 first units are below breakeven — incremental volume from FAT/SAT delivery in 2026 would actually compound losses before optimisation kicks in. Management targets a 35% MFE220 build-cost reduction and 10% efficiency improvement in the Mark II by 2028 2026-03-30 update; if achieved, this could swing economics, but this is an "if" not a "when". On a 10-20% revenue beat above current expectations of ~£5m near-term contracted revenue, operating profit would remain materially negative; meaningful operating-leverage benefit only kicks in beyond £30-50m of revenue, which the filings do not visibility-provide.

Value-trap signals

  • Repeated dilution at falling prices (Dec 2024 at 7.5p; Aug 2025 at 5p — a 33% step-down)
  • Auditor going concern material uncertainty in 2024 annual report
  • £9.1m of impairments in FY2024 — capitalised development costs (£5.6m), inventory write-down (£1.5m), PP&E (£1.1m), inventory on onerous contract (£0.9m) 2025-05-01 final results
  • Onerous contract provisions recurring in 2024 and 2025
  • Multiple guidance misses on FAT/SAT/first-revenue timing
  • CEO taking 20% salary in shares to preserve cash in July 2025 2025-07-31 RNS
  • Trading suspension 29 May 2026 with undisclosed reason

Earnings vs. expectations

The filings disclose no formal analyst consensus and no explicit profit guidance — management has guided to operational milestones (FAT, SAT, first revenues) rather than to financial outcomes. The pattern is one of repeated milestone slippage: MFE220 FAT was guided "H2 2025" in April 2025 2025-05-01, then "Q4 2025/Q1 2026" in July 2025, then "Q1 2026" in September 2025, then now in April 2026 with SAT in Q3 2026 2026-03-30. First commercial revenues likewise have rolled from 2024 → 2025 → 2026 → Q3 2026. The pattern is consistently "miss" on timing, with the technology destination delivered but the schedule never. There is no quantitative earnings expectation against which to score beats and misses.

Conviction

4 — high, on the call that the shares are very materially overvalued.

Anchors of conviction: (i) the company is pre-revenue with £4k of H1 2025 revenue and a £3.4m H1 loss against a £6.8bn market cap — this is qualitatively impossible to defend on any rational methodology; (ii) the company has placed equity at 5p as recently as September 2025 with willing director participation, providing a near-term independently-validated price reference; (iii) the trading suspension of 29 May 2026 indicates the market price is itself under official review.

Caveats: (i) without seeing the suspension announcement, I cannot rule out a transformative event (large strategic investor, government supply contract) that re-rates the equity; (ii) the licensing-model optionality is genuinely option-like — fat-tail outcomes exist but cannot be probability-weighted accurately from the filings.

Filings consulted · 24

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-05-29Suspension Clean Power Hydrogen Plc2026-05-29_9591675_suspension-clean-power-hydrogen-plc.md1.00
  2. 2026-03-30Operations Amp Trading Update2026-03-30_9497001_operations-amp-trading-update.md0.85
  3. 2025-09-30Interim Results2025-09-30_9138768_interim-results.md0.77
  4. 2025-08-28Result OF Placing And Subscription2025-08-28_9078429_result-of-placing-and-subscription.md0.59
  5. 2025-08-28Proposed Placing Subscription And Retail Offer2025-08-28_9076533_proposed-placing-subscription-and-retail-offer.md0.59
  6. 2025-07-31Corporate Update And Proposed Fundraising2025-07-31_9014670_corporate-update-and-proposed-fundraising.md0.59
  7. 2025-06-19Result OF Agm2025-06-19_8938839_result-of-agm.md0.26
  8. 2025-05-21Posting OF Annual Report And Notice OF Agm2025-05-21_8888785_posting-of-annual-report-and-notice-of-agm.md0.62
  9. 2025-05-01Final Results2025-05-01_8855684_final-results.md0.65
  10. 2024-12-19Result OF Placing And Subscription2024-12-19_8620206_result-of-placing-and-subscription.md0.46
  11. 2024-12-18Proposed Placing Subscription And Retail Offer2024-12-18_8619645_proposed-placing-subscription-and-retail-offer.md0.46
  12. 2024-11-26Operational Update And Proposed Fundraising2024-11-26_8572043_operational-update-and-proposed-fundraising.md0.46
  13. 2024-09-272024 Interim Results2024-09-27_8443124_2024-interim-results.md0.58
  14. 2024-09-05Publication OF Interim Results2024-09-05_8401242_publication-of-interim-results.md0.58
  15. 2024-06-19Result OF Agm2024-06-19_8268619_result-of-agm.md0.20
  16. 2024-05-10Posting OF Annual Report And Notice OF Agm2024-05-10_8187304_posting-of-annual-report-and-notice-of-agm.md0.43
  17. 2024-04-192023 Full Year Results2024-04-19_8145957_2023-full-year-results.md0.45
  18. 2023-09-21Interim Results2023-09-21_7768510_interim-results.md0.41
  19. 2023-06-21Result OF Agm2023-06-21_7586643_result-of-agm.md0.14
  20. 2023-05-17Posting OF Annual Report And Notice OF Agm2023-05-17_7530005_posting-of-annual-report-and-notice-of-agm.md0.24
  21. 2023-04-13Investor Presentation2023-04-13_7487869_investor-presentation.md0.17
  22. 2022-09-23Interim Results2022-09-23_7065506_interim-results.md0.23
  23. 2022-07-19Result OF Agm2022-07-19_7080247_result-of-agm.md0.07
  24. 2022-05-27Group Annual Report And Financial Statements2022-05-27_7029032_group-annual-report-and-financial-statements.md0.24

This research note was authored by a large language model after reading 22 regulatory filings published between 2022-05-27 and 2026-05-29. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.